Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis
Metrics: PDF 736 views | HTML 1075 views | ?
Claudia Marchetti1,*, Francesca De Felice2,*, Angela Musella1, Innocenza Palaia1, Marco Monti1, Daniela Musio2, Ludovico Muzii1, Vincenzo Tombolini2, Pierluigi Benedetti Panici1
1 Department of Gynecological and Obstetrical Sciences and Urological Sciences, “Sapienza” University of Rome, Rome, Italy
2 Department of Radiotherapy, Policlinico Umberto I “Sapienza” University of Rome, Rome, Italy
* These authors have equal contribution to this study
Francesca De Felice, email:
Keywords: ovarian cancer; dose-dense; carboplatin; paclitaxel; weekly
Received: April 29, 2016 Accepted: June 29, 2016 Published: August 05, 2016
Aim: Three weeks paclitaxel and carboplatin has been considered the standard of care for primary treatment of ovarian cancer (OC). Whether weekly therapy will further improve the clinical outcomes or not is still unclear. We conducted a meta-analysis to compare the two regimens.
Method: Articles were selected with a systematic approach, using PubMed databases. Trials concerning comparison between carboplatin plus weekly paclitaxel (dose-dense regimen) and carboplatin plus paclitaxel every 3 weeks were considered. Outcomes included overall survival (OS), progression free survival (PFS) and severe acute toxicity.
Results: Dose-dense regimen was associated with significant improvement of PFS compared with standard schedule, with HR of 0.73 (95% CI 0.61-0.88, p = 0.001). There was no difference in OS between treatment regimens (HR 0.95, 95% CI 0.77-1.16, p=0.06), as well as in term of severe acute toxicity.
Conclusion: Dose-dense regimen is superior to standard schedule in terms of PFS. Further studies are necessary to firmly confirm this evidence in advanced OC treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.